Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Uncover the rewards credit card that offers the best benefits to enhance your financial experience.
28,009 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Warren Buffett has long championed simple, cost-effective investing. This Warren Buffett-approved investment, a low-c...
Bitcoin briefly topped $67,000 on a wave of geopolitical headlines, but a veteran crypto analyst warns the rally coul...
XRP remains in a tight battle between support and supply as July markets unfold. A breach of key levels could set XR...
Silver miners surged 124% over the past year and platinum climbed 89%, but volatility has risen. Investors face a cle...
Intel has powered a 492% surge in a year, but a wave of insider selling has traders weighing how durable the rebound ...
Long-dated Treasuries extended a six-year losing streak in 2025. A new, low-profile ETF is engineered to profit if ra...
Micron has surged into a market-defining position as traders weigh earnings potential against memory-price risk. Anal...
Three dividend aristocrats have boosted payouts for a combined 187 years, delivering steady passive income for invest...
Vanguard’s FTSE Developed Markets ETF has posted stronger gains than the S&P 500 in 2026, drawing renewed investor in...
Anthropic aims to go public this fall, but mounting regulatory pressures risk undercutting its valuation. Investors a...
Salesforce faces leadership questions as founder Marc Benioff approaches three decades at the helm. The company is st...